Parkinson’s UK invests in clinical trial of a potential treatment that could protect brain cells Date 2 July 2024
Parkinson's UK invests in first trial of pioneering treatment in people with Parkinson’s Date 1 July 2024
Disappointing results from trials of vaccines for Parkinson’s, but hope for the future Date 12 August 2022 2 clinical trials aiming to reduce the clumps of troublesome alpha-synuclein to protect brain cells have, so far, failed to show a clear benefit for people with Parkinson’s.
Celebrating neuroscience in spring 2023 Date 4 August 2022 We are partnering with the British Neuroscience Association (BNA) to plan and deliver the BNA International Festival of Neuroscience 2023.
Progress towards Apple Watch based tracking of symptoms Date 17 June 2022 An app that links to Apple Watch technology has been granted FDA approval to help monitor some motor symptoms experienced by people with Parkinson’s.
Save Parkinson’s clinical research. Take part today Date 8 June 2022 We’re calling on the Parkinson’s community to take part in 5 important clinical studies that are currently at risk of closure.
Parkinson's UK invests in drug development Date 23 August 2021 We've invested a further £490,000 to support the development of drugs to protect mitochondria and treat Parkinson's.
Oxford researchers find molecule that may slow or stop the progress of Parkinson's Date 29 September 2020 Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Results from stem cell therapy surgery announced Date 14 May 2020 A US-based team has published results after treating one individual with an experimental stem cell therapy. The therapy involved surgically transplanting new brain cells, made from the patient's own skin, into the brain of a man with Parkinson's.
Promising results from a phase II study for people with early-stage Parkinson’s Date 8 October 2019 A phase II clinical trial of tavapadon, a drug developed by Cerevel Therapeutics, has shown improvements in movement symptoms. The results have been announced on the company website.
Investing in a new treatment for dyskinesia Date 24 January 2018 We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
Research on caffeine to diagnose Parkinson's Date 4 January 2018 Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.